(“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of ...
PASADENA, Calif.-- (BUSINESS WIRE)-- $arwr -- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is ...
Encouraging safety and pharmacodynamic activity observed with HB2198 in normal healthy volunteers was presented with ...
SIGA Technologies (NASDAQ: SIGA), a commercial stage pharmaceutical company, announced today that Dennis Hruby, Ph.D., ...
Conference call to take place on Friday, November 13 at 8:30 a.m. U.S Eastern Time. HENDERSON, Nev., Nov. 9, 2026 /PRNewswire ...
Two new data presentations underscore the diagnostic and clinical utility of genome and exome sequencing for pediatric ...
FDA feedback supports planned bioequivalence-based 505(b)(2) development pathway for once-daily treprostinil prodrug patch ...
Third Quarter 2026 Financial Results. Total revenue of $35.1 million, compared with $20.6 million in the third quarter of ...
Delix Therapeutics, a clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens, today ...
Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, driven by continued adoption among U.S. urologists and ...
(Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule ...
Reneurx therapy achieved at least 30% pain reduction at three months versus 63.8% with intraarticular corticosteroids; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results